[ad_1]
IVERIC bio, Inc. (NASDAQ stock code:I understand) (“Company”), today announced that it has begun underwriting the public offering of its common stock. In addition, the company intends to grant the underwriters a 30-day option to purchase up to 15% of the common stock. The sale is restricted by the market and other conditions, and there is no guarantee whether or when the sale will be completed, nor can it guarantee the actual scale or terms of the sale. All shares will be offered by the company.
Cowen, Credit Suisse and Stifel acted as bookrunners for this issue. Wedbush PacGrow served as the lead manager of this release.
On March 5, 2021, it submitted the shelf registration statement on Form S-3 (document number 333-253897) of the common stock to be issued to the United States Securities and Exchange Commission (“SEC”), and declared it effective April 9, 2021 . This issuance will only be conducted through the prospectus supplement and accompanying prospectus forming part of the registration statement.Supplementary documents related to the initial prospectus are being submitted to the US Securities and Exchange Commission and will be made available on the US Securities and Exchange Commission’s website www.sec.govThe supplement to the preliminary prospectus and a copy of the accompanying prospectus can also be obtained by contacting: Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long…
The full story on Benzinga.com
[ad_2]
Source link
